Copyright © Lemma Pharmaceuticals, Inc. All Rights Reserved.

Lemma Pharmaceutical is focused on development of nanoparticle based delivery platforms to enhance the therapeutic safety and efficacy of potent agents that face PK and TOX challenges, and can overcome chemo and radiotherapy resistant solid tumors.

  • Lipostaur™ ready for formulation optimization, by group that developed liposomal agents VesCan®, AmBisome® and DaunoXome®

  • Optimized formulation undergo dose ranging studies, then enter pre-clinical development for an IND in glioblastoma.

  • Lipostaur™ in testing in various cancer models in addition to brain cancer, including colon, prostate, liver, and pancreatic cancer.